The provisions of this section shall be null, void, and of no force and effect on and after July 1, 2021.
(1)  In this section:
(a)  "Anti-epileptic drug" means:
(i)   A drug used for the treatment of epilepsy; or
(ii)  A drug used to treat or prevent seizures.
(b)  "Drug product selection" means the selection of a therapeutically equivalent drug, including a generic version for the prescribed brand, a branded version for the prescribed generic, or a generic version by one (1) manufacturer for a generic version by a different manufacturer.
(c)  "Epilepsy" means a neurological condition characterized by recurrent seizures.
(d)  "Seizure" means an acute clinical change secondary to a brief disturbance in the electrical activity of the brain.
(2)  When a prescriber has specified that a drug is prescribed for the treatment of epilepsy or seizures, pharmacy personnel who perform drug product selections shall:
(a)  Notify the prescriber of such drug product selection via facsimile, telephone message or any other appropriate means to the prescriber’s place of business; and
(b)  Provide the patient or the patient’s representative with notification of the selection.
(3)  Nothing in this section shall delay the dispensing of a valid prescription for an anti-epileptic drug.